NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals
— In the United States, approximately 3 out of every 4 patients do not meet target LDL-c goals1; in Europe, about 4 out of every 5 patients in the highest risk group do not meet their target LDL-c goals2 — — 82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 … [Read more…]